We are live on ! Find out more
SGMO

SANGAMO THERAPEUTICS INC
SGMO

Delisted

SGMO was delisted on the 4th of May, 2026.

Back to rankings

118 hedge funds and large institutions have $241M invested in SANGAMO THERAPEUTICS INC in 2017 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 29 increasing their positions, 40 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more capital invested

Capital invested by funds: $127M → $241M (+$114M)

57% more call options, than puts

Call options by funds: $3.91M | Put options by funds: $2.49M

0.56% more ownership

Funds ownership: 58.69% → 59.26% (+0.56%)

9% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 22

6% less funds holding

Funds holding: 126 → 118 (-8)

28% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 40

Holders
118
Holders Change
-8
Holders Change %
-6.35%
% of All Funds
2.94%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
20
Increased
29
Reduced
40
Closed
22
Calls
$3.91M
Puts
$2.49M
Net Calls
+$1.42M
Net Calls Change
-$669K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$22.5M
2
CC
Casdin Capital
New York
+$3.41M
3
GIM
Granahan Investment Management
Massachusetts
+$3.19M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.01M
5
BBA
Baker Bros. Advisors
New York
+$1.91M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$2.16M
2
NC
Nexthera Capital
New York
-$1.53M
3
Deutsche Bank
Deutsche Bank
Germany
-$1.12M
4
Renaissance Technologies
Renaissance Technologies
New York
-$982K
5
WA
Wasatch Advisors
Utah
-$787K
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
101
Nelson Capital Management
California
$16K -$1.6K -400 -12%
Zurich Cantonal Bank
102
Zurich Cantonal Bank
Switzerland
$12K – – –
Nisa Investment Advisors
103
Nisa Investment Advisors
Missouri
$10K +$8.02K +2,000 New
SIM
104
Sonora Investment Management
Arizona
$9.36K +$2.01K +500 +38%
BWP
105
Baldwin Wealth Partners
Massachusetts
$8K – – –
TDC
106
Thompson Davis & Co
Virginia
$8K +$6.02K +1,500 New
Simplex Trading
107
Simplex Trading
Illinois
$8K +$6.44K +1,605 New
MAM
108
Meeder Asset Management
Ohio
$7K -$11.1K -2,773 -66%
BKA
109
Brick & Kyle Associates
Pennsylvania
$6K – – –
AF
110
Allworth Financial
California
$5K – – –
AG
111
Advisor Group
Arizona
$5K +$4.01K +1,000 New
Creative Planning
112
Creative Planning
Kansas
$5K +$4.01K +1,000 New
CG
113
Cutler Group
California
$4K -$6.79K -1,693 -68%
BNP Paribas Financial Markets
114
BNP Paribas Financial Markets
France
$2.36K -$3.04K -759 -63%
Bank of Montreal
115
Bank of Montreal
Ontario, Canada
$2K – – –
Fifth Third Bancorp
116
Fifth Third Bancorp
Ohio
$2K – – –
ASN
117
Advisory Services Network
Georgia
$2K +$1.2K +300 New
QCG
118
Quadrant Capital Group
Ohio
$2K +$2.06K +514 New
O
119
OrbiMed
New York
– -$2.16M -707,400 Closed
NC
120
Nexthera Capital
New York
– -$1.53M -503,000 Closed
Renaissance Technologies
121
Renaissance Technologies
New York
– -$982K -321,819 Closed
PCM
122
Piermont Capital Management
Missouri
– -$505K -165,569 Closed
SA
123
Sicart Associates
New York
– -$311K -101,950 Closed
AFM
124
Anson Funds Management
Texas
– -$306K -100,209 Closed
Tudor Investment Corp
125
Tudor Investment Corp
Connecticut
– -$201K -65,800 Closed
2 3 4
5
6

SGMO Hedge Fund Activity: Q1 2017 in Review

118 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q1 2017, worth a combined $241M — up 90% from $127M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of SGMO and 20 opened new positions — a net loss of 2 holders — while 40 trimmed existing stakes and 29 added.

The largest buyer was BlackRock, adding an estimated $22.5M. The largest seller was OrbiMed, exiting entirely with an estimated $2.16M sold.

  • 118 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q1 2017, down from 126 in Q4 2016.
  • Funds reported $241M of SANGAMO THERAPEUTICS INC stock for Q1 2017, up 90% quarter-over-quarter.
  • 20 funds opened new SANGAMO THERAPEUTICS INC positions in Q1 2017 and 22 closed out, a net change of -2 holders.
  • The largest SANGAMO THERAPEUTICS INC buyer in Q1 2017 was BlackRock, an estimated $22.5M added.
  • The largest SANGAMO THERAPEUTICS INC seller in Q1 2017 was OrbiMed, an estimated $2.16M sold.

Based on aggregated 13F filings for Q1 2017.